Main Page Content

Director: Dr. Sindhu Johnson​

The Toronto Scleroderma Program is a health care network comprised of three academic hospitals:  Mount Sinai Hospital, Toronto Western Hospital, and Toronto General Hospital​, all affiliated with the University of Toronto. As a quaternary referral center, we see approximately 700 patients with the scleroderma spectrum of disorders annually.

The Toronto Scleroderma Program provides patient care, education and research in the scleroderma spectrum of disorders. Conditions may include:

  • Eosinophilic fasciitis
  • Mixed connective tissue disease
  • Morphea
  • Raynaud's phenomenon
  • Systemic sclerosis

Key Research Areas

We are actively engaged in both translational and clinical research with the goals of improving our understanding of this disease, finding better treatments, and improving patients' lives. Our team investigates:

  • Development of classification criteria for systemic sclerosis and its subsets
  • Epidemiology of cancer in systemic sclerosis
  • Epoprostenol rescue therapy for scleroderma associate pulmonary arterial hypertension
  • Lung transplantation in advanced scleroderma lung disease
  • Sjögren's syndrome in systemic sclerosis
  • Use of autologous stem cells for the healing of scleroderma ulcers

Our program works with the UHN Pulmonary Hypertension Program, Interstitial Lung Disease Clinic​ and Toronto Lung Transplant Program. We collaborate with other national and international Scleroderma Centres, and are a member institution of the Scleroderma Clinical Trials Consortium.

Our program also provides advanced training to graduate students, international students, physicians and allied health professionals who wish to develop expertise in this area.

For more information about participating in our research, please contact:

Dr. Sindhu Johnson

Phone: 416 603 6417